Physician profile
Steven Koenig
NPI 1669513321
$242,365.26
in general payments reported to CMS, 2019-2025
33 companies · $36K in 2025
The $36K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $28K · 2021: $23K · 2022: $25K · 2023: $85K · 2024: $46K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $79K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Travel and Lodging: $26K · Food and Beverage: $4,467 · Education: $228 · Gift: $17.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $79,093.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $57,200.00 |
| Travel and Lodging | $25,850.30 |
| Food and Beverage | $4,466.96 |
| Education | $228.33 |
| Gift | $17.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $227,659.62 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Insmed, INC. | $9,469.96 | 2023-2024 | Arikayce |
| Astrazeneca Pharmaceuticals LP | $1,731.39 | 2019-2024 | Fasenra, Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $731.65 | 2020-2023 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Grifols USA, LLC | $433.94 | 2021-2024 | Prolastin-C Liquid |
| Gilead Sciences, INC. | $393.65 | 2021-2024 | Veklury |
| Regeneron Healthcare Solutions, INC. | $304.60 | 2019-2024 | Dupixent |
| Mylan Specialty L.P. | $292.07 | 2019-2024 | Yupelri |
| Genzyme Corporation | $249.88 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $218.67 | 2019-2023 | |
| Axsome Therapeutics, INC. | $137.38 | 2023 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $120.01 | 2021-2024 | Glassia, Aralast |
| Sunovion Pharmaceuticals INC. | $102.63 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $63.29 | 2021-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Verona Pharma, INC. | $54.72 | 2025 | Ohtuvayre |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $52.48 | 2019-2023 | Smartvest |
| Fisher & Paykel Healthcare INC | $37.23 | 2024 | Fisher & Paykel Healthcare |
| Inogen, INC. | $33.00 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Pulmonx Corporation | $31.66 | 2019-2022 | |
| Amgen INC. | $24.71 | 2020 | |
| Baxter Healthcare | $23.83 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Inspire Medical Systems, INC. | $21.53 | 2024 | Inspire |
| Livanova USA, INC. | $19.89 | 2019 | |
| Harmony Biosciences LLC | $18.35 | 2025 | |
| United Therapeutics Corporation | $18.12 | 2024 | Tyvaso |
| Vifor Pharma, INC. | $17.61 | 2024 | Zemaira |
| Mallinckrodt Hospital Products INC. | $17.27 | 2022 | |
| Mayne Pharma Commercial LLC | $17.06 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $15.59 | 2024 | Lumryz |
| Shire North American Group INC | $14.43 | 2019 | |
| Biomerieux INC | $14.00 | 2024 | Vidas Nephrocheck |
| Allergan, INC. | $13.81 | 2020 | |
| Intercept Pharmaceuticals, INC. | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Koenig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.